NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free CNTB Stock Alerts $1.71 -0.05 (-2.84%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.7450-Day Range$1.22▼$2.2052-Week Range$0.53▼$2.84Volume86,638 shsAverage Volume130,788 shsMarket Capitalization$94.22 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Connect Biopharma alerts: Email Address Connect Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside280.1% Upside$6.50 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.54 to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 starsMedical Sector352nd out of 931 stocksPharmaceutical Preparations Industry161st out of 432 stocks 3.5 Analyst's Opinion Consensus RatingConnect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageConnect Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Connect Biopharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.10% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently increased by 73.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTB. Previous Next 2.0 News and Social Media Coverage News SentimentConnect Biopharma has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Connect Biopharma this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Connect Biopharma are expected to decrease in the coming year, from $0.54 to ($0.63) per share.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Connect Biopharma Stock (NASDAQ:CNTB)Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Read More CNTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTB Stock News HeadlinesMay 22, 2024 | globenewswire.comConnect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe AsthmaMay 7, 2024 | globenewswire.comConnect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe AsthmaApril 26, 2024 | finance.yahoo.comConnect Biopharma Holdings Limited (CNTB)April 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)April 16, 2024 | globenewswire.comConnect Biopharma Reports Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic PartnershipsApril 7, 2024 | marketwatch.comADRs Advance; Connect Biopharma Climbs 19%April 1, 2024 | marketwatch.comADRs End Higher; Connect Biopharma Climbs 26%March 19, 2024 | tmcnet.comConnect Biopharma to Participate in H.C. Wainwright 2n? Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2024 | globenewswire.comConnect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 5, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Connect Biopharma Holdings Limited - Depositary Receipt () (CNTB) with Buy RecommendationFebruary 22, 2024 | benzinga.comConnect Biopharma Hldgs Stock (NASDAQ:CNTB) Dividends: History, Yield and DatesFebruary 12, 2024 | finance.yahoo.comConnect Biopharma Appoints Industry Veteran James Huang to Board of DirectorsJanuary 29, 2024 | finance.yahoo.comWill Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?December 15, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Connect Biopharma Holdings (CNTB) and Inspire Medical Systems (INSP)December 15, 2023 | seekingalpha.comCNTB Connect Biopharma Holdings LimitedDecember 12, 2023 | morningstar.comConnect Biopharma Holdings Ltd ADR CNTBDecember 12, 2023 | marketwatch.comConnect Biopharma Shares Jump on Positive Results for Asthma Treatment TrialDecember 12, 2023 | msn.comConnect Biopharma gains as asthma candidate succeeds in mid-stage trialDecember 12, 2023 | finance.yahoo.comConnect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent AsthmaDecember 11, 2023 | finance.yahoo.comConnect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023November 30, 2023 | finance.yahoo.comStonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus ManagementNovember 28, 2023 | finance.yahoo.comIs Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?November 21, 2023 | msn.comWhy Is Skin Disease-Focused Connect Biopharma Stock Lower Today?November 21, 2023 | msn.comConnect Biopharma stock rises on positive data from dermatitis mAbSee More Headlines Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNTB CUSIPN/A CIK1835268 Webwww.connectbiopharm.com Phone18587271045Fax+1 8586147007Employees81Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+280.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio4.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.93Miscellaneous Outstanding Shares55,100,000Free Float42,650,000Market Cap$94.22 million OptionableOptionable Beta-0.49 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Wubin Pan M.B.A. (Age 59)Ph.D., Co-Founder, President & Chairman of the Board of Directors Dr. Zheng Wei Ph.D. (Age 60)Co-Founder, CEO & Director Mr. Steven Chan (Age 52)Chief Financial Officer Mr. Jiang Bian J.D.General Counsel & Chief Compliance OfficerDr. Lei Sun Ph.D. (Age 60)VP of Biologics & Head of CMC Dr. Raul Collazo Ph.D.VP & Global Head of Medical AffairsDr. Malinda V. Longphre Ph.D.VP & Head of US Clinical OperationsMore ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTZevra TherapeuticsNASDAQ:ZVRAAdlai NortyeNASDAQ:ANLFibroBiologicsNASDAQ:FBLGVerrica PharmaceuticalsNASDAQ:VRCAView All CompetitorsInstitutional OwnershipKeudell Morrison Wealth ManagementBought 8,500 shares on 5/7/2024Ownership: 0.036%View All Institutional Transactions CNTB Stock Analysis - Frequently Asked Questions Should I buy or sell Connect Biopharma stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTB shares. View CNTB analyst ratings or view top-rated stocks. What is Connect Biopharma's stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for Connect Biopharma's stock. Their CNTB share price targets range from $5.00 to $8.00. On average, they predict the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 280.1% from the stock's current price. View analysts price targets for CNTB or view top-rated stocks among Wall Street analysts. How have CNTB shares performed in 2024? Connect Biopharma's stock was trading at $1.18 at the start of the year. Since then, CNTB shares have increased by 44.9% and is now trading at $1.71. View the best growth stocks for 2024 here. Are investors shorting Connect Biopharma? Connect Biopharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 54,100 shares, an increase of 73.4% from the April 30th total of 31,200 shares. Based on an average daily trading volume, of 165,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold. View Connect Biopharma's Short Interest. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $150 million in an initial public offering on Friday, March 19th 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. Who are Connect Biopharma's major shareholders? Connect Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Keudell Morrison Wealth Management (0.04%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTB) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
